منابع مشابه
Lead time and overdiagnosis.
In this issue of the Journal, Etzioni et al. (1) suggest a novel approach to estimating overdiagnosis in breast cancer. However, there is a key assumption in their method regarding the nature of overdiagnosis that is unlikely to hold and leads to an underestimate of the overdiagnosis rate. To understand this assumption, we need to go back to basic definitions. Lead time is the time from detecti...
متن کاملOverdiagnosis and overtreatment over time.
Overdiagnosis and overtreatment are often thought of as relatively recent phenomena, influenced by a contemporary combination of technology, specialization, payment models, marketing, and supply-related demand. Yet a quick glance at the historical record reveals that physicians and medical manufacturers have been accused of iatrogenic excess for centuries, if not millennia. Medicine has long ha...
متن کاملLead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
BACKGROUND The time by which prostate-specific antigen (PSA) screening advances prostate cancer diagnosis, called the lead time, has been reported by several studies, but results have varied widely, with mean lead times ranging from 3 to 12 years. A quantity that is closely linked with the lead time is the overdiagnosis frequency, which is the fraction of screen-detected cancers that would not ...
متن کاملDoes screening mammography lead to overdiagnosis of invasive breast cancer?
www.aafp.org/afp Volume 87, Number 6 ◆ March 15, 2013 What does this article say? Jill: This is a prospective historical cohort study looking at the rate of overdiagnosis of invasive breast cancer between 1986 and 2005 in 39,888 Norwegian women 50 to 69 years of age. Norway piloted mammographic screening in four counties that represented 40 percent of the eligible population in 1996 before impl...
متن کاملThe overdiagnosis nightmare: a time for caution
Overdiagnosis (and overtreatment) of cancers not bound to become symptomatic during lifetime is an unavoidable drawback of mammography screening. The magnitude of overdiagnosis has been estimated to be in the range of 5-10%, and thus acceptable in view of screening benefits as to reduced mortality. In a recent research article in BMC Women's Health, Jørgensen, Zahl and Gøtzsche suggest that ove...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI Journal of the National Cancer Institute
سال: 2014
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/dju346